News and Updates
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
VLEVA's EU-subsidiemonitor 2021-2022; I3, het Interregional Innovation Investment Instrument
In the 'EU-subsidiemonitor 2021-2022' VLEVA investigates how Flemish organisations participate in European subsidised programs. This time with a focus for Interregional Innovation Investment Instrument - I3.
-
I3 finances International cooperations building innovative value chains.
-
Discover how Flanders’ FOOD with the HIGHFIVE-project stimulates digital and green growth in the agrofood-value chain in Europe.
-
Get information on the open calls in I3.
Deadline for strand 1 and strand 2a are both on december 5th 2024. Recordings of the information sessions can be found here.
Related News
|
2024-11-05
|
2 weeks ago |
NCP Flanders team: Reshuffle of responsibilities of our NCP Advisors - Horizon Europe... |
|
2024-09-02
|
2 months ago |
Horizon Europe Impact training session and Proposal workshop coming up this Autumn |
|
2024-04-17
|
7 months ago |
Feedback opportunity for Horizon Europe work programme 2025 now open |
|
2024-04-12
|
7 months ago |
New video series: European Partnerships under Horizon Europe |
|
2024-03-25
|
7 months ago |
Communication on EU Biotech and Biomanufacturing Initiative out now |
|
2024-02-20
|
9 months ago |
Survey on new KIC on water, marine and maritime sectors and ecosystems (WMM) |
|
2023-10-09
|
1 year ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
|
2023-09-27
|
1 year ago |
NCP Flanders survey still open until 13 October |
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Latest News
1484 articles available search in articlesDeployment: Best use of technologies
Procurement: Better Internet for Kids (BIK) Platform – EU Coordination
The European Commission (DG CONNECT) has launched the following procurement procedure: Better Internet for Kids (BIK) Platform – EU Coordination (EC-CNECT/LUX/2024/OP/0097) The EU-funded Better Internet for Kids portal (at https://better-internet-for-kids.europa.eu) and the associated coordination tasks are the main subject of th... read more
Digital, Industry & Space AI, data & cloud
Commission consultation on AI Act prohibitions and AI system definition
The European Commission’s Artificial Intelligence (AI) Office has launched a targeted stakeholders consultation process on the future guidelines on the AI system definition and the implementation of AI practices that pose unacceptable risks under the AI Act. The guidelines will help national competent authorities as well as providers and dep... read more
Digital, Industry & Space AI, data & cloud
First draft of General-Purpose Artificial Intelligence Code of Practice
The European Commission has published the first draft of the General-Purpose Artificial Intelligence (AI) Code of Practice. The rules governing general-purpose AI models under the AI Act will come into application in August 2025. The Code of Practice aims to facilitate the proper implementation of these rules and will play a crucial role in guidin... read more
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
